Grapheton
Addressing Critical Health Problems
Neurological Diseases
– Alzheimers: 50M Worldwide
– Parkinsons: 10M Worldwide
– Epilepsy: 50M Worldwide
– Stroke: 1 out of 4 People
Injury
– Back and Spinal Cord
– Concussion and Brain Trauma
– Pain Reduction
– Controlling Prostheses
– Understanding and Communicating with Human Brain
Grapheton
US Market Share and Frocast for Impantable Neural Probes for Parkinson’s Disease
Grapheton
Problems We’re Addressing
Current implantable neural probes (DBD) for treating severe forms of Parkinson’s disease have electrodes that do not last longer than 12 to 18 months; therefore, requiring repeat cranial surgeries that are expensive, inconvenient, and prone to infection. Therefore, there is a need for probes with corrosion resistance and longevity of 5 to 10 years.
Current implantable systems record only electrical signals from the brain and provide a limited window to the complex electrical and chemical environment in areas of treatment. Also causes several associated side effects.
Grapheton
Our Value Proposition
Provide Degradation-Resistant Neural Probes
– Longer lasting requires less number of surgeries for patients
– Integration of results allows tailored, on-demand electrical stimulation which eliminates most of the side-effects
Grapheton
Wearable and Implantable Brain-Machine Interface Devices
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .